Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EIDX Eidos Therapeutics (EIDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Eidos Therapeutics Stock (NASDAQ:EIDX) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Eidos Therapeutics alerts:Sign Up Key Stats Today's Range$122.21▼$122.2150-Day Range$120.98▼$128.5152-Week Range$28.39▼$132.54VolumeN/AAverage Volume128,113 shsMarket Capitalization$4.75 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Receive EIDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EIDX Stock News HeadlinesNext Deus Ex game seemingly canceled as Eidos Montreal is affected by layoffsNovember 3 at 12:14 PM | msn.comStellar Blade: How To Drain Water In Eidos 7 (Oblivion Side Quest)May 7, 2024 | msn.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 5, 2024 | Porter & Company (Ad)Stellar Blade: How to Solve Monorail Puzzle on Eidos 7April 26, 2024 | msn.comThe Anglo File: Game Over for Board Lapses at EidosFebruary 3, 2024 | thestreet.comDeus Ex game canceled as nearly 100 Eidos-Montreal staff laid offJanuary 31, 2024 | msn.comEmbracer Group reportedly cancels unannounced Deus Ex game, lays off staff at Eidos MontrealJanuary 31, 2024 | msn.comEmbracer lays off 97 Eidos employees and cancels new Deus Ex gameJanuary 31, 2024 | msn.comSee More Headlines EIDX Stock Analysis - Frequently Asked Questions How were Eidos Therapeutics' earnings last quarter? Eidos Therapeutics, Inc. (NASDAQ:EIDX) issued its earnings results on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.08. The firm earned $0.13 million during the quarter. When did Eidos Therapeutics IPO? Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager. What other stocks do shareholders of Eidos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY). Company Calendar Last Earnings10/29/2020Today11/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EIDX CUSIPN/A CIKN/A Webwww.eidostx.com Phone415-887-1471FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.21% Return on Assets-53.04% Debt Debt-to-Equity Ratio0.14 Current Ratio11.10 Quick Ratio11.10 Sales & Book Value Annual Sales$26.69 million Price / Sales177.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book26.74Miscellaneous Outstanding Shares38,873,000Free FloatN/AMarket Cap$4.75 billion OptionableNot Optionable Beta-0.16 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:EIDX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eidos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eidos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.